Bryn Mawr Capital Management LLC decreased its holdings in shares of The Chemours Company (NYSE:CC – Free Report) by 89.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,756 shares of the specialty chemicals company’s stock after selling 23,709 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Chemours were worth $47,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of CC. Appian Way Asset Management LP acquired a new stake in shares of Chemours during the third quarter worth $34,151,000. Vision One Management Partners LP acquired a new stake in shares of Chemours during the third quarter worth $28,252,000. Scopia Capital Management LP acquired a new stake in shares of Chemours during the third quarter worth $13,623,000. FMR LLC lifted its holdings in shares of Chemours by 3.5% during the third quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock worth $368,650,000 after buying an additional 618,361 shares in the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in shares of Chemours during the fourth quarter worth $5,731,000. Institutional investors and hedge funds own 76.26% of the company’s stock.
Analyst Upgrades and Downgrades
CC has been the subject of a number of research reports. The Goldman Sachs Group dropped their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Mizuho dropped their price target on Chemours from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Truist Financial assumed coverage on Chemours in a research note on Tuesday, January 28th. They issued a “buy” rating and a $27.00 price target for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Chemours in a research note on Thursday, December 12th. Finally, Morgan Stanley dropped their price target on Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $23.56.
Chemours Stock Performance
Chemours stock opened at $16.77 on Friday. The Chemours Company has a 12-month low of $15.10 and a 12-month high of $29.83. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The business’s 50-day moving average price is $18.09 and its two-hundred day moving average price is $18.91. The stock has a market cap of $2.51 billion, a PE ratio of 29.42 and a beta of 1.81.
Chemours (NYSE:CC – Get Free Report) last released its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm had revenue of $1.36 billion for the quarter, compared to analysts’ expectations of $1.37 billion. As a group, analysts expect that The Chemours Company will post 2.03 earnings per share for the current fiscal year.
Chemours Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Friday, February 28th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 5.96%. The ex-dividend date is Friday, February 28th. Chemours’s dividend payout ratio (DPR) is currently 175.44%.
About Chemours
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Articles
- Five stocks we like better than Chemours
- What is a buyback in stocks? A comprehensive guide for investors
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Airline Stocks – Top Airline Stocks to Buy Now
- DuPont’s Electronics Spinoff: The Start of Something Big
- Insider Selling Explained: Can it Inform Your Investing Choices?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC – Free Report).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.